Common Stock
- Symbol
- EXOZ
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
EXOZNASDAQEQUITYCurrent
Item 7.01 Regulation FD Disclosure On June 24, 2026, the Company issued a press release announcing that it was being awarded a $2 Million NIH grant to advance cannaboinoid analogs for drug discovery.…
EXOZYMES INC. · 8-K · Filed 2026-06-26
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery Award allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential future pharmaceutical assets and validates the Company’s ability to make rare cannabinoids and new cannabinoid-like molecules. NIH-backed work on the two-year grant is expected to begin on July 1, 2026, and represents the second biosolution in eXoZymes’ pipeline after NCT advancing towards partnership and commercialization. Total non-dilutive funding awarded to eXoZymes is now almost $20 million, validating the scalable nature of the Company’s platform LOS ANGELES, CA - June 24, 2026 - eXoZymes Inc. (NASDAQ: EXOZ) - a pioneer of AI-enhanced enzymes that enable scalable manufacturing of nutraceuticals and novel pharmaceuticals - today announced that it has received a Notice of Award from the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH) for a Phase IIB Small Business Innovation Research (SBIR) grant totaling $2,028,518. The NIH funded work is expected to begin July 1, 2026, and will support eXoZym…
Open exhibit ↗